PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pfizer (PFE) will report its second-quarter 2024 earnings on Jul 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.22 billion and 45 cents per share ...

As regards Pfizer, oncology sales ... of Pfizer’s diversified portfolio of drugs, particularly oncology, ... currently trade at 8.24 forward earnings, higher than 7.41 for Pfizer.

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

Pfizer's Q3 earnings soar on COVID revenue but stock dips as market doubts long-term growth. ... Breast cancer drug Ibrance saw revenues fall sequentially, to just under $1.1bn, ...

The New York-based drug company (PFE) had net income of $4.465 billion, or 78 cents a share, for the quarter, after a loss of $2.382 billion, or 42 cents a share, in the year-earlier period.

Despite the topline growth during the quarter, Pfizer’s net income also dropped 98% to $41 million, while its adjusted diluted earnings per share (EPS) slid 11% to $0.60. In light of its quarterly ...

Additionally, Pfizer’s rapid advancement of several cancer drugs into phase 3 development opens the door to new blockbusters, including vepdegestrant (breast), sigvotatug vedotin (lung ...

Pfizer missed first quarter earnings Thursday amid a volatile macro ... including the $43 billion for Seagen and its oncology pipeline, ... One drug alone, Padcev, is expected to add $3.1 ...

Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting ...